Beirne Wealth Consulting Services LLC Invests $506,000 in argenex SE $ARGX

Beirne Wealth Consulting Services LLC acquired a new stake in argenex SE (NASDAQ:ARGX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 686 shares of the company’s stock, valued at approximately $506,000.

Several other large investors have also recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. grew its holdings in argenex by 9.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,946 shares of the company’s stock valued at $1,435,000 after buying an additional 167 shares during the period. HighTower Advisors LLC boosted its position in shares of argenex by 6.7% in the third quarter. HighTower Advisors LLC now owns 5,948 shares of the company’s stock worth $4,387,000 after acquiring an additional 371 shares during the last quarter. Naviter Wealth LLC boosted its position in shares of argenex by 8.3% in the third quarter. Naviter Wealth LLC now owns 866 shares of the company’s stock worth $639,000 after acquiring an additional 66 shares during the last quarter. Assetmark Inc. grew its holdings in argenex by 8.8% in the third quarter. Assetmark Inc. now owns 9,818 shares of the company’s stock valued at $7,242,000 after purchasing an additional 791 shares during the period. Finally, Atria Investments Inc increased its position in argenex by 1.8% during the third quarter. Atria Investments Inc now owns 2,758 shares of the company’s stock worth $2,034,000 after purchasing an additional 50 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ARGX. HC Wainwright lifted their price target on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a report on Friday, October 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a report on Wednesday, January 21st. Wedbush reissued an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research report on Wednesday, January 14th. Stifel Nicolaus upped their price target on argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Wells Fargo & Company lifted their price objective on argenex from $1,264.00 to $1,317.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $986.78.

argenex Price Performance

Shares of ARGX opened at $821.96 on Tuesday. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The stock’s 50-day moving average is $834.55 and its two-hundred day moving average is $803.03. The stock has a market cap of $50.86 billion, a PE ratio of 35.29, a P/E/G ratio of 0.71 and a beta of 0.37.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.